Period July – September 2021
• Net sales: 0 (0) TSEK.
• Other operating revenues: 423 (2,673) TSEK.
• Profit from financial items: -10,225 (-6,532) TSEK.
• Earnings per share: -0.52 (-0.91) SEK.
Period January – September 2021
• Net sales: 0 (0) TSEK.
• Other operating revenues: 6,380 (8,892) TSEK.
• Profit from financial items: -36,483 (-18,587) TSEK.
• Earnings per share: -2.22 (-2.82) SEK.
• Liquidity as per the end of the reporting period: 66,087 (35,245) TSEK.
• Equity ratio as per the end of the reporting period: 95 (83)%.
Events during the period
• CombiGene initiates GMP production of CG01 for the first-in-human study (26 July 2021).
• Patent approved in the U.S. and Russia for CombiGenes gene therapy candidate CG01 (July 28, 2021).
• CombiGene applies for international patent protection for the vectors developed within the CGT2 project (August 25).
Events after the period
• CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene therapy candidate CG01.
• CombiGene’s Horizon 2020 project successfully completed with a final payment of approximately EUR 500,000, which means that CombiGene has received the full grant of EUR 3.36 million.